drugset / Trial / NCT05175274
Colchicine Use for Primary Prevention of Coronary Artery Disease
Phase 3
Not yet recruiting
6792 enrolled
Qingdao Central Hospital
Qingdao Municipal Hospital · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Colchicine has been widely used as an anti-gout medicine in the past decades. Some recent clinical trials have proved that low-dose colchicine can be used as a secondary prevention drug for coronary artery disease because of its anti-inflammatory mechanism. However, the effect on primary prevention has not been observed sufficiently. The objective of this study is to determine whether colchicine reduces the incidence of CAD in patients and its safety for long-term use.
Timeline
- Start
- 2022-12-06
- Primary completion
- 2027-03-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Colchicine | Small molecule | 0.5 mg | — |